On January 28, 2022, Homology Medicines, Inc. entered into an equity securities purchase agreement with a newly formed adeno-associated virus (AAV) vector manufacturing company (Newco), Oxford Biomedica (US), Inc. and Oxford Biomedica plc. Effective as of the Closing, Tim Kelly will assume the role of Chief Executive Officer and Chairman of the Board of Newco and will no longer serve as the Chief Operating Officer of Homology.